Cellectar Biosciences, Inc. Unrealized Gain (Loss) on Derivatives
Cellectar Biosciences, Inc. (CLRB) reported Unrealized Gain (Loss) on Derivatives of $2.23 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-05-20.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2015-05-20
- Cellectar Biosciences, Inc. unrealized gain (loss) on derivatives for fiscal 2014 was $2.23M.
| Period end | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|
| 2014-12-31 | $2.23M 10-K · filed 2015-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |